Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities, driven by policy support and strong performance in the stock market [1][2]. Market Performance - On August 1, the A-share market saw a mixed performance with the Shanghai Composite Index down 0.37%, Shenzhen Component down 0.17%, and ChiNext down 0.24%, while over 3,300 stocks rose [1]. - The TCM sector witnessed a surge, with the Shenwan TCM Index rising by 1.78%, placing it among the top-performing secondary industry indices [2]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research [2]. - The State Council's 2025 policy emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [2]. Company Performance - Notable companies such as Darentang, Jilin Aodong, and Buchang Pharmaceutical reported significant net profit growth, with Darentang's net profit expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [4][5]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [5]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced market strategies and sales [5]. Financial Highlights - The following companies reported substantial net profit growth in the first half of 2025: - Darentang: 19.2 billion yuan, up 192% [6] - Jilin Aodong: 12.63 billion yuan, up 135% [6] - Buchang Pharmaceutical: 5.98 billion yuan, up 158.41% [6] - The overall performance of TCM companies indicates a strong recovery and growth trajectory, supported by favorable market conditions and policy initiatives [4][5].

Group 1 - A total of 19 listed companies have released their semi-annual reports for 2025, with notable net profit figures from companies such as Darentang, Jilin Aodong, and Buchang Pharma [1] - Darentang's net profit is expected to reach between 1.84 billion to 2 billion yuan, representing a year-on-year growth of 180% to 204%, primarily due to the disposal of a 12% stake in its joint venture Tianjin Shike, resulting in a gain of 1.54 billion yuan [1] - Jilin Aodong and Buchang Pharma also reported net profit growth, with both companies achieving year-on-year increases of over 100% [1] Group 2 - Changcheng Securities highlighted Darentang's successful development of "Jingwanhong Skin Factor," which transforms traditional Chinese medicine wisdom into effective skincare ingredients, indicating potential growth in the Chinese herbal skincare market [1] - Tianmu Pharmaceutical has successfully turned losses into profits by enhancing its market presence in pharmaceuticals, health products, and medical devices, leading to significant increases in product sales and overall profitability [1] - Tianmu Pharmaceutical's stock reached the daily limit increase, with notable investment from well-known trader "Xiaoguo Yangjia," who purchased 9.53 million yuan worth of shares [1]

Core Insights - Jilin Aodong reported a closing price of 19.04 yuan as of August 1, 2025, with a slight increase of 0.42% and a turnover rate of 1.65% [1] - The company experienced a significant net outflow of main funds amounting to 33.51 million yuan, representing 8.9% of the total transaction amount [1] - The latest quarterly report shows total revenue of 623 million yuan, a year-on-year decrease of 27.71%, while net profit attributable to shareholders reached 517 million yuan, a year-on-year increase of 259.75% [1] Financial Performance - Total revenue for Q1 2025 was 623 million yuan, down 27.71% year-on-year [1] - Net profit attributable to shareholders was 517 million yuan, up 259.75% year-on-year [1] - Non-recurring net profit was 488 million yuan, reflecting a year-on-year increase of 75.56% [1] - Current ratio stands at 1.871, quick ratio at 1.525, and debt-to-asset ratio at 11.43% [1] Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. was established in 1993 and is located in Yanbian Korean Autonomous Prefecture [2] - The company primarily engages in the pharmaceutical manufacturing industry [2] - The registered capital of the company is approximately 11.96 billion yuan, with the same amount in paid-in capital [1][2] Investment and Intellectual Property - Jilin Aodong has invested in 47 external enterprises and participated in one bidding project [2] - The company holds 216 trademark registrations and 8 patents, along with 3 administrative licenses [2]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has developed a dual-driven path of "old medicine new making" and "one ginseng drives regional prosperity" over 42 years, focusing on innovation while inheriting traditional practices [1] Product Positioning - The company emphasizes product standards as a passport to high-end markets, striving to enhance product quality and brand positioning [2] Product Development - The "Anshen Bnona Liquid," a compound traditional Chinese medicine, has captured an 80% market share since its inception in 1983, transitioning from local to national standards [3] - The company has expanded its ginseng product line, with 44 medicinal products and over 100 functional foods, projecting a revenue of over 200 million yuan from ginseng products in 2024 [3] Source Foundation - Jilin Aodong adheres to the principle that quality raw materials ensure quality products, with significant investments in GAP-certified bases for deer and local medicinal materials [4] - The company has established over 6,000 acres of medicinal material bases and has received multiple quality certifications for its ginseng and deer products [4] Technological Empowerment - The introduction of an intelligent extraction control system in 2003 has automated the production of Anshen Bnona Liquid, ensuring product safety and consistency [5] - The same technological advancements are being applied to the ginseng sector, enhancing production efficiency and quality assurance [5] Brand Development - The company has successfully leveraged national advertising and sports sponsorships to enhance brand recognition, with plans to expand its ginseng products into international markets [6][7] Research and Development - Continuous R&D efforts have demonstrated the efficacy of Anshen Bnona Liquid in treating neurodegenerative conditions, with recent studies highlighting the potential of deer antler in Alzheimer's treatment [8][9] - The company is also exploring new applications for ginseng saponins in treating various health conditions, aiming to enter the billion-yuan market for brain health [9] Policy Environment - Jilin Aodong benefits from favorable policies that support the development of traditional Chinese medicine and the enhancement of its deer breeding practices, ensuring long-term growth and competitive advantage [10][12]

Group 1: Research Breakthroughs - The study published in "Nature Aging" reveals that extracellular vesicles from antler blastema progenitor cells can reverse bone loss and mitigate aging-related phenotypes in mice and macaques, effectively making the biological age of macaques younger by an average of 2.14 years [1][4] - The research highlights the unique regenerative capabilities of deer antlers, which are the only mammalian organs that can completely regenerate periodically, making them an ideal model for studying aging and regeneration [2][3] Group 2: Company Developments - Jilin Aodong, the largest deer product processing company in China, has over 60 years of experience in breeding deer and has continuously developed and researched deer antler products, including the "Anshen Bnona Liquid," which is now supported by scientific evidence for its traditional efficacy [5][6] - The company has achieved significant market share in the traditional Chinese medicine sector, holding 60%-70% of the market for calming and brain-enhancing products, with annual sales exceeding 700 million yuan [6][8] Group 3: Policy and Industry Trends - The Jilin provincial government has issued a development plan for the deer industry (2025-2029), encouraging the exploration of classic formulations and modern biotechnological applications to enhance the efficacy of deer products [8][9] - Jilin Aodong aims to integrate traditional deer antler value with cutting-edge biotechnology, positioning itself to capture a significant share of the brain health market, which is projected to be worth hundreds of billions [7][9]

Market Overview - The Chinese medicine sector rose by 1.0% on July 29, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] Top Gainers in Chinese Medicine Sector - Foci Pharmaceutical (002644) closed at 10.69, up 9.98% with a trading volume of 841,300 shares and a turnover of 876 million yuan [1] - Zhongsheng Pharmaceutical (002317) also rose by 9.98% to 19.73, with a trading volume of 1,168,400 shares and a turnover of 2.26 billion yuan [1] - Other notable gainers include: - Zhendong Pharmaceutical (300158) up 6.66% to 7.69 [1] - Huasen Pharmaceutical (002907) up 6.50% to 18.51 [1] - Kangjia Pharmaceutical (600557) up 5.61% to 16.58 [1] Top Losers in Chinese Medicine Sector - Qidi Pharmaceutical (000590) fell by 2.65% to 12.13, with a trading volume of 134,500 shares and a turnover of 163 million yuan [2] - Zhenbaodao (603567) decreased by 2.21% to 12.40, with a trading volume of 182,700 shares and a turnover of 227 million yuan [2] - Other notable losers include: - Yunnan Baiyao (000538) down 1.20% to 55.82 [2] - Kangmei Pharmaceutical (600518) down 0.94% to 2.10 [2] Capital Flow Analysis - The Chinese medicine sector saw a net inflow of 798 million yuan from institutional investors, while retail investors experienced a net outflow of 625 million yuan [2][3] - Notable net inflows from institutional investors include: - Zhongsheng Pharmaceutical (002317) with a net inflow of 308 million yuan [3] - Zhendong Pharmaceutical (300158) with a net inflow of 96.32 million yuan [3] - Conversely, significant net outflows from retail investors were observed in: - Zhongsheng Pharmaceutical (002317) with a net outflow of 98.88 million yuan [3] - Zhendong Pharmaceutical (300158) with a net outflow of 65.62 million yuan [3]

Core Viewpoint - The biopharmaceutical industry in the Shenzhen Stock Exchange is showing a stable and positive performance in the first half of 2025, with 56 companies expected to achieve a net profit between 3.8 billion to 5 billion yuan [1] Group 1: Performance Forecasts - Dabo Medical is expected to achieve a net profit of approximately 230 million to 250 million yuan, representing a year-on-year increase of 66.37% to 80.84% [2] - Aosaikang is projected to realize a net profit of 135 million to 175 million yuan, with a year-on-year growth rate of 78.58% to 131.50% [2] - Jilin Aodong anticipates a net profit of about 1.236 billion to 1.290 billion yuan, reflecting a year-on-year increase of 130% to 140% [3] Group 2: Innovation and R&D - Dabo Medical emphasizes product innovation and international development strategies to maintain healthy business growth [2] - Aosaikang is focusing on the commercialization of its first innovative drug, which marks a significant milestone in its transformation [2] - Aosaikang has over 40 drugs in various stages of development, including more than ten innovative drugs in clinical stages [5] Group 3: Strategic Adjustments - Companies are actively adjusting their operational strategies and optimizing cost structures to enhance resilience and profitability [4] - Dabo Medical plans to strengthen its core business through innovation and international expansion [4] - Jilin Aodong aims to focus on its pharmaceutical core business while leveraging its brand advantages for steady revenue and profit growth [4]

Core Insights - The research led by Chinese scientists reveals that extracellular vesicles from antler blastema progenitor cells can reverse bone loss and mitigate aging-related phenotypes in mice and macaques, providing a new treatment strategy for age-related diseases such as Alzheimer's and osteoporosis [1][3][11] - The findings are expected to drive the traditional deer industry towards biotechnology, creating a new ecosystem that combines ancient Chinese medicine wisdom with modern biotechnological advancements [3][4][18] Company Overview - Jilin Aodong (000623) is the largest deer product processing company in China, with over 60 years of experience in breeding sika deer and continuous research on deer antler [3][4][18] - The scientific discoveries related to deer antler have validated the traditional efficacy of Jilin Aodong's product, Anshen Bnona Liquid, which is believed to contain "longevity" secrets that will be gradually unveiled with the research outcomes [3][12][16] Market Potential - Jilin Aodong aims to integrate traditional deer antler value with cutting-edge biotechnology, potentially capturing a significant share of the "brain health" market, which is projected to be worth hundreds of billions [4][18] - The company has a strong foothold in the market, holding 60%-70% of the national market share for Anshen Bnona Liquid, which generates over 700 million yuan in annual sales [16][17] Research and Development - The research on deer antler regeneration has opened new avenues for anti-aging interventions, particularly in reversing bone loss and improving multi-organ aging [11][19] - Jilin Aodong has been actively investing in research and development, achieving breakthroughs in deer breeding technology and establishing a comprehensive disease prevention system [19][20] Policy Support - The company benefits from favorable government policies aimed at promoting the deer industry, including the recent development plan for the sika deer industry (2025-2029) that encourages the exploration of classic formulas and modern biotechnological applications [20][21] - Jilin Aodong has already obtained GMP compliance and "blue hat" certification for its health products, positioning itself well to leverage policy support for quality enhancement [20]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has evolved from a state-owned deer farm established in 1957 to a modern enterprise with three major business segments: pharmaceuticals, finance, and health care, occupying an industrial park of 122 hectares, showcasing significant growth and innovation in the industry [1][3]. Group 1: Company Overview - Jilin Aodong operates 20 subsidiaries, primarily focused on pharmaceuticals, including six drug processing companies and five sales companies, which form the core production capacity of the company [3]. - The company holds 624 production approval numbers, with 312 for traditional Chinese medicine and 312 for chemical drugs, including 46 exclusive varieties and dosage forms [3]. Group 2: Financial Performance - Jilin Aodong anticipates a profit exceeding 1.2 billion yuan in the first half of the year, driven by the sustained performance of its three business segments [6]. - The investment return from Guangfa Securities, in which Jilin Aodong holds a 20.11% stake, is expected to grow by 40.69% year-on-year for the 2024 fiscal year [6]. Group 3: Business Strategy and Future Outlook - The company is expanding into the "big health" sector through subsidiaries focused on health technology and enzyme production, which are seen as new growth points [8]. - Jilin Aodong emphasizes technological innovation to foster new productive forces and accelerate industrial transformation, contributing to local employment and tax revenue [8].

Report Basic Information - Reported Company: Jilin Aodong [16] - Industry: Chemical Pharmaceuticals [2] - Research Date: July 17, 2025 [16] - Company Representatives: Wang Zhenyu (Director, Deputy General Manager, Secretary of the Board), Zhao Renhe (Director of the Board Office, Securities Affairs Representative) [16] Participating Institutions - "Innovation Sailing, King's Moment - The 20th Pharmaceutical Hundred Listed Companies Exchange Meeting (Beijing Station)" [17] - Guosheng Securities (Representative: Zhang Yu) [17] - Beijing Hongdao (Representative: Tang Yulin) [17] - Yimin Fund (Representative: Gui Guan) [17] - CITIC Securities Asset Management (Representative: Peng Kang) [17] - Ginkgo Capital (Representative: Zhang Haijun) [17] Institution Proportion - Others: 33% [21] - Securities Companies: 17% [21] - Investment Companies: 17% [21] - Fund Management Companies: 17% [21] - Asset Management Companies: 17% [21] Core Business Highlights Business Revenue Structure in 2024 - Total revenue from three major business segments (traditional Chinese medicine, chemical drugs, and chain pharmacy wholesale and retail) reached 2.273761 billion yuan, with traditional Chinese medicine contributing 1.6055413 billion yuan (61.50%), chemical drugs 276.8538 million yuan (10.61%), and chain pharmacy business 391.366 million yuan (14.99%) [22] - Revenue from the health - care business was 212.1299 million yuan, accounting for 8.13% of the total revenue [22] Key Product Analysis - **An Shen Bu Nao Ye**: With a large target audience due to the increasing number of insomnia sufferers, its sales growth is supported by consumer trust in the brand and product efficacy, and the unique geographical advantage of its raw materials. It is mainly sold outside hospitals. The company implements an "An Shen +" combination strategy to drive performance growth [22][23] - **Xue Fu Zhu Yu Kou Fu Ye**: A well - recognized product with multiple honors. Its selection in the national Chinese patent medicine procurement alliance's volume - based procurement in 2024 is expected to expand sales. The company will continue brand building, strengthen cooperation with major pharmaceutical chains, and promote clinical use [24] Project Progress - **Chinese Medicine Formula Granule Project**: As of December 31, 2024, 228.776 million yuan of the raised funds had been used. Multiple workshops passed the GMP compliance inspection on January 23, 2025. The company has obtained 525 "Listing Filing Certificates for Chinese Medicine Formula Granules" and is focusing on market development [25] Investment in GF Securities - As of March 31, 2025, the company and its wholly - owned subsidiaries held 1,529,911,767 shares of GF Securities, accounting for 20.11% of the total shares. In 2024, the company's investment income from GF Securities was 174.94045 million yuan, a 40.69% increase from the previous year [25][26] Dividend Policy - The company has formulated a "Three - Year (2024 - 2026) Shareholder Return Plan", increasing the frequency and optimizing the rhythm of dividends. It has a 17 - year history of cash dividends, with a cumulative cash dividend of 4.505 billion yuan since listing. It aims to enhance the stability and predictability of dividends in the future [26]